- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Colchicine an effective and cheap medication to reduce MACE
Overview
Cardiac events are a huge burden in field of medicine. A recent study showed that colchicine significantly reduces MACE risk in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Colchicine reduced the risk of repeat vessel revascularization, stent thrombosis, and stroke. The study appears in the BMJ journal Open Heart.
PCI is the preferred coronary reperfusion strategy that induces endothelial trauma which may scale an inflammatory response. This may increase the likelihood of further major adverse cardiovascular events (MACE). Colchicine is a cheap and widely used anti-inflammatory that has shown promise in improving cardiovascular outcomes.
For more information check out the full story on the link below:
Colchicine Cheap And Low-Risk Medication To Reduce MACE In Patients Undergoing PCI: BMJ
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)